Clinically Correlated MicroRNAs in the Diagnosis of Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

被引:0
|
作者
Jiang, Min [1 ,2 ,3 ]
Li, Xuelian [3 ]
Quan, Xiaowei [3 ]
Li, Xiaoying [3 ]
Zhou, Baosen [1 ,2 ,3 ]
机构
[1] China Med Univ, Affiliated Hosp 1, Dept Clin Epidemiol, Shenyang 110001, Liaoning, Peoples R China
[2] China Med Univ, Affiliated Hosp 1, Ctr Evidence Based Med, Shenyang 110001, Liaoning, Peoples R China
[3] China Med Univ, Sch Publ Hlth, Dept Epidemiol, Shenyang 110122, Liaoning, Peoples R China
基金
中国国家自然科学基金;
关键词
BLOOD MONONUCLEAR-CELLS; NONINVASIVE BIOMARKERS; PROGNOSTIC BIOMARKER; PLASMA MICRORNAS; EXPRESSION; SERUM; SPUTUM; IDENTIFICATION; MIR-21; MIRNAS;
D O I
10.1155/2018/5930951;5930951
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
(1) Background. Non-small cell lung cancer (NSCLC) has a high mortality rate. MiRNAs have been found to be diagnostic biomarkers for NSCLC. However, controversial results exist. We conducted this meta-analysis to evaluate the diagnostic value of miRNAs for NSCLC. (2) Methods. Databases and reference lists were searched. Pooled sensitivity (SEN), specificity (SPE), and area under the curve (AUC) were applied to examine the general diagnostic efficacy, and subgroup analysis was also performed. (3) Results. Pooled SEI, SPE, and AUC were 85%, 88%, and 0.93, respectively, for 71 studies. Multiple miRNAs (AUC: 0.96) obtained higher diagnostic value than single miRNA (AUC: 0.86), and the same result was found for Caucasian population (AUC: 0.97) when compared with Asian (AUC: 0.91) and Caucasian/African population (AUC: 0.92). MiRNA had higher diagnostic efficacy when participants contained both smokers and nonsmokers (AUC is 0.95 for imbalanced group and 0.91 for balanced group) than when containing only smokers (AUC: 0.90). Meanwhile, AUC was 0.91 for both miR-21 and miR-210. (4) Conclusions. Multiple miRNAs such as miR-21 and miR-210 could be used as diagnostic tools for NSCLC, especially for the Caucasian and nonsmoking NSCLC.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Efficacy and safety of Toliparibumab for the treatment of non-small cell lung cancer: a systematic review and meta-analysis
    Liu, Yihao
    Yang, Liangyu
    Duan, Zhixuan
    Cheng, Qian
    Liu, Minghui
    Zhang, HongBing
    Zhao, HongLin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [22] SMARCA4 alterations in non-small cell lung cancer: a systematic review and meta-analysis
    Wankhede, Durgesh
    Grover, Sandeep
    Hofman, Paul
    JOURNAL OF CLINICAL PATHOLOGY, 2024, 77 (07) : 457 - 463
  • [23] Prognostic value of Ezrin expression in non-small cell lung cancer: a systematic review and meta-analysis
    Li, Shuang-Jiang
    Huang, Jian
    Zhang, Wen-Biao
    Fan, Jun
    Che, Guo-Wei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (07): : 13664 - +
  • [24] Optimal duration of chemotherapy for advanced non-small cell lung cancer: A systematic review and meta-analysis
    Soon, Yu
    Askie, Lisa
    Stockler, Martin
    Boyer, Michael
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S450 - S451
  • [25] Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis
    Waser, Nathalie A.
    Quintana, Melanie
    Schweikert, Bernd
    Chaft, Jamie E.
    Berry, Lindsay
    Adam, Ahmed
    Vo, Lien
    Penrod, John R.
    Fiore, Joseph
    Berry, Donald A.
    Goring, Sarah
    JNCI CANCER SPECTRUM, 2024, 8 (03)
  • [26] Nintedanib in Combination With Chemotherapy in the Treatment of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Alhadeethi, Abdulhameed
    Awwad, Sara Adel
    Abed, Mohamed
    Amin, Ahmed Mostafa
    Aboelkhier, Menna M.
    Yassin, Mazen Negmeldin Aly
    Morsi, Maha H.
    Kashbour, Muataz Omar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)
  • [27] Efficacy and safety of neoadjuvant immunotherapy in non-small cell lung cancer: a systematic review and meta-analysis
    Xu, Ke
    Ni, Juan
    Wu, Xiaodi
    Xie, Jingyuan
    Chen, Mo
    Zhang, Fang
    Liu, Hongbing
    Zhan, Ping
    Lv, Tangfeng
    Song, Yong
    AME MEDICAL JOURNAL, 2022, 7
  • [28] Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis
    Olivares-Hernandez, Alejandro
    Roldan-Ruiz, Jonnathan
    Miramontes-Gonzalez, Jose Pablo
    Toribio-Garcia, Irene
    Garcia-Hernandez, Juan Luis
    Posado-Dominguez, Luis
    Bellido-Hernandez, Lorena
    Cruz-Hernandez, Juan Jesus
    Fonseca-Sanchez, Emilio
    del Barco-Morillo, Edel
    CHINESE CLINICAL ONCOLOGY, 2023, 12 (06)
  • [29] The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature
    J P Sculier
    L Ghisdal
    T Berghmans
    F Branle
    J J Lafitte
    F Vallot
    A P Meert
    F Lemaitre
    E Steels
    A Burniat
    C Mascaux
    M Paesmans
    British Journal of Cancer, 2001, 84 : 1150 - 1155
  • [30] Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
    Yang, Fang
    Wang, Yucai
    Tang, Lin
    Mansfield, Aaron Scott
    Adjei, Alex A. A.
    Leventakos, Konstantinos
    Duma, Narjust
    Wei, Jia
    Wang, Lifeng
    Liu, Baorui
    Molina, Julian R. R.
    FRONTIERS IN ONCOLOGY, 2022, 12